177 related articles for article (PubMed ID: 38588272)
1. Immunotherapy in the treatment of advanced or recurrent endometrial cancer.
Grau-Bejar JF; Farinas-Madrid L; García-Duran C; García-Illescas D; Mazzeo R; Oaknin A
Clin Adv Hematol Oncol; 2024 Apr; 22(3):129-139. PubMed ID: 38588272
[TBL] [Abstract][Full Text] [Related]
2. Latest advances in immuno-oncology for endometrial cancer: single-agent and combination regimens.
Richardson M; Chase DM
Curr Opin Obstet Gynecol; 2024 Feb; 36(1):1-8. PubMed ID: 37792525
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors for recurrent endometrial cancer.
Mutlu L; Harold J; Tymon-Rosario J; Santin AD
Expert Rev Anticancer Ther; 2022 Mar; 22(3):249-258. PubMed ID: 35176955
[TBL] [Abstract][Full Text] [Related]
4. Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis.
Bartoletti M; Montico M; Lorusso D; Mazzeo R; Oaknin A; Musacchio L; Scambia G; Puglisi F; Pignata S
Cancer Treat Rev; 2024 Apr; 125():102701. PubMed ID: 38422895
[TBL] [Abstract][Full Text] [Related]
5. Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer.
Kasherman L; Ahrari S; Lheureux S
Future Oncol; 2021 Mar; 17(8):877-892. PubMed ID: 33251877
[TBL] [Abstract][Full Text] [Related]
6. PARP inhibitors and immunotherapy in ovarian and endometrial cancers.
Miller RE; Lewis AJ; Powell ME
Br J Radiol; 2021 Dec; 94(1128):20210002. PubMed ID: 33882241
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in endometrial cancer.
Mahdi H; Chelariu-Raicu A; Slomovitz BM
Int J Gynecol Cancer; 2023 Mar; 33(3):351-357. PubMed ID: 36878570
[TBL] [Abstract][Full Text] [Related]
8. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma.
Di Dio C; Bogani G; Di Donato V; Cuccu I; Muzii L; Musacchio L; Scambia G; Lorusso D
Gynecol Oncol; 2023 Feb; 169():27-33. PubMed ID: 36493574
[TBL] [Abstract][Full Text] [Related]
9. Advanced and recurrent endometrial cancer: State of the art and future perspectives.
Tronconi F; Nero C; Giudice E; Salutari V; Musacchio L; Ricci C; Carbone MV; Ghizzoni V; Perri MT; Camarda F; Gentile M; Berardi R; Scambia G; Lorusso D
Crit Rev Oncol Hematol; 2022 Dec; 180():103851. PubMed ID: 36257537
[TBL] [Abstract][Full Text] [Related]
10. Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer.
Hill BL; Graf RP; Shah K; Danziger N; Lin DI; Quintanilha J; Li G; Haberberger J; Ross JS; Santin AD; Slomovitz B; Elvin JA; Eskander RN
Int J Gynecol Cancer; 2023 Apr; 33(4):504-513. PubMed ID: 36750267
[TBL] [Abstract][Full Text] [Related]
11. Previously treated recurrent or advanced endometrial cancer in England: A real-world observational analysis.
Heffernan K; Nikitas FS; Shukla U; Camejo HS; Knott C
Gynecol Oncol; 2022 Aug; 166(2):317-325. PubMed ID: 35752507
[TBL] [Abstract][Full Text] [Related]
12. [New drug approval: Dostarlimab - second line in advanced MSI endometrial cancer].
Galienne M; Rodrigues M
Bull Cancer; 2021; 108(7-8):675-676. PubMed ID: 33994164
[No Abstract] [Full Text] [Related]
13. Mismatch repair and clinical response to immune checkpoint inhibitors in endometrial cancer.
Antill Y; Buchanan DD; Scott CL
Cancer; 2022 Mar; 128(6):1157-1161. PubMed ID: 34875102
[TBL] [Abstract][Full Text] [Related]
14. Application of Immune Checkpoint Inhibitors in Gynecological Cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors?
Lee SM; Lee S; Cho HW; Min KJ; Hong JH; Song JY; Lee JK; Lee NW
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674491
[TBL] [Abstract][Full Text] [Related]
15. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Therapies for Melanoma.
Buchbinder EI
Hematol Oncol Clin North Am; 2021 Feb; 35(1):99-109. PubMed ID: 33759776
[TBL] [Abstract][Full Text] [Related]
17. Optimizing immunotherapy for gynecologic cancers.
Rubinstein MM; Makker V
Curr Opin Obstet Gynecol; 2020 Feb; 32(1):1-8. PubMed ID: 31833942
[TBL] [Abstract][Full Text] [Related]
18. [A decade of checkpoint inhibitors: current standard of care and future trends].
Reischer A; Kruger S; von Bergwelt-Baildon M
Dtsch Med Wochenschr; 2021 Sep; 146(17):1108-1118. PubMed ID: 34448187
[TBL] [Abstract][Full Text] [Related]
19. The current status of immunotherapy in the treatment of primary advanced and recurrent endometrial cancer.
Fontenot VE; Tewari K
Curr Opin Obstet Gynecol; 2023 Feb; 35(1):34-42. PubMed ID: 36595647
[TBL] [Abstract][Full Text] [Related]
20. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
